{"entity":{"id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in triple-negative breast cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT07281976 by Nanjing Leads Biolabs Co.,Ltd, with 220 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: LBL-024 for Injection, albumin-bound Paclitaxel injection and Toripalimab Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07281976","url":"https://clinicaltrials.gov/study/NCT07281976"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07281976","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":220,"outcomes":[]},"route":"/trials/nct07281976/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}